Search: id:"swepub:oai:DiVA.org:uu-522681" >
Health care resourc...
-
Hjalte, FridaSwedish Inst Hlth Econ, Lund, Sweden.;IHE Inst Halso & Sjukvardsekon, Rabygatan 2, S-22361 Lund, Sweden.
(author)
Health care resource use, diagnostic delay and disease burden in transthyretin amyloid cardiomyopathy in Sweden
- Article/chapterEnglish2023
Publisher, publication year, extent ...
-
Taylor & Francis,2023
-
electronicrdacarrier
Numbers
-
LIBRIS-ID:oai:DiVA.org:uu-522681
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-522681URI
-
https://doi.org/10.1080/07853890.2023.2292686DOI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:154554876URI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
Aims: To estimate healthcare resource use and direct healthcare costs of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in Sweden over 12 months across severity stages as defined by the New York Heart Association (NYHA). Secondary to investigate the current diagnostic trajectory for patients with ATTR-CM in Sweden.Methods: A stratified inclusion of patients with a confirmed diagnosis of ATTR-CM in different NYHA classes. Data was extracted from medical records in two cardiology clinics in Sweden. Healthcare resource use data were retrospectively collected for 12 months.Results: 38 patients were included, of whom 7 were in NYHA class II, 20 in class III and 4 in class IV. The total cost of health care per patient increased from SEK 69,000 (euro6800) in NYHA stage II, SEK 219,000 (euro21,500) in NYHA stage III, to SEK 638,000 (euro62,900) in stage IV, mainly due to an increase in inpatient stays. Mean time (standard deviation, SD) from any cardiac related diagnosis prior to ATTR-CM diagnosis was 3.5 (3.1) years.Conclusions: Advanced ATTR-CM stages are associated with significant healthcare costs, as patients more often require resource-intensive inpatient care. The current diagnostic trajectory of ATTR-CM in this study was characterized by a diagnostic delay of several years.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Norlin, Jenny M.Swedish Inst Hlth Econ, Lund, Sweden.
(author)
-
Alverbäck-Labberton, LindaPfizer AB, Stockholm, Sweden.
(author)
-
Johansson, KatarinaPfizer AB, Stockholm, Sweden.
(author)
-
Wikström, GerhardUppsala universitet,Kardiologi(Swepub:uu)gewik021
(author)
-
Eldhagen, PerKarolinska Univ Hosp, Karolinska Inst, Dept Med, Stockholm, Sweden.;Karolinska Univ Hosp, Dept Cardiol, Stockholm, Sweden.
(author)
-
Swedish Inst Hlth Econ, Lund, Sweden.;IHE Inst Halso & Sjukvardsekon, Rabygatan 2, S-22361 Lund, Sweden.Swedish Inst Hlth Econ, Lund, Sweden.
(creator_code:org_t)
Related titles
-
In:Annals of Medicine: Taylor & Francis55:20785-38901365-2060
Internet link
Find in a library
To the university's database